Fansheng Ran

Nantong, 226001, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Discovery of 5-fluoro-aminopyrimidine derivatives as dual BTK/FLT3 inhibitors for the treatment of rheumatoid arthritis.

Discovery of 5-fluoro-aminopyrimidine derivatives as dual BTK/FLT3 inhibitors for the treatment of rheumatoid arthritis.

Journal: Molecular diversity
Published: December 10, 2025

Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluation.

Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluation.

Journal: European journal of medicinal chemistry
Published: October 20, 2025

Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.

Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.

Journal: Bioorganic chemistry
Published: November 01, 2022

Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects.

Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects.

Journal: European journal of medicinal chemistry
Published: August 18, 2022

Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.

Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.

Journal: Journal of medicinal chemistry
Published: July 25, 2022

Recent development of BTK-based dual inhibitors in the treatment of cancers.

Recent development of BTK-based dual inhibitors in the treatment of cancers.

Journal: European journal of medicinal chemistry
Published: December 10, 2021

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.

Journal: Journal of natural products
Published: November 22, 2021

TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.

TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.

Journal: Theranostics
Published: October 14, 2021

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

Journal: European journal of medicinal chemistry
Published: October 05, 2021

Overview of piperlongumine analogues and their therapeutic potential.

Overview of piperlongumine analogues and their therapeutic potential.

Journal: European journal of medicinal chemistry
Published: February 13, 2021

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.

Journal: Bioorganic chemistry
Published: January 26, 2021

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.

Journal: Bioorganic chemistry
Published: December 18, 2019
Showing 1-12 of 17

Last Updated: 09/26/2026